This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original articles
Frías, J. P. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2107519 (2021)
Rosenstock, J. et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet https://doi.org/10.1016/S0140-6736(21)01324-6 (2021)
Related articles
Perreault, L. et al. Novel therapies with precision mechanisms for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 17, 364–377 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Starling, S. The dawning of dual-acting incretin drugs. Nat Rev Endocrinol 17, 513 (2021). https://doi.org/10.1038/s41574-021-00540-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-021-00540-y